The long-term health and economic benefits of DOTS implementation on Ecuador

Canadian Journal of Public Health

Volumn 97, Issue 1, 2006, Pages 14-19

  Oxlade, Olivia ^a   Vaca, Judyth ^b   Romero, Elizabeth ^c   Schwartzman, Kevin ^a   Graham, Brian ^b   Hernandez, Lucero ^b   Tannenbaum, Terry ^b   Menzies, Dick ^a  

^a MCGILL UNIVERSITY   (Canada)

^b Canadian Lung Association   (Canada)

^c Ecuadorian National TB Programme   (Ecuador)

Author keywords

Control; Cost effectiveness; Decision analysis; Treatment; Tuberculosis

Indexed keywords

TUBERCULOSTATIC AGENT;

ARTICLE; CANADA; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DECISION MAKING; DIRECTLY OBSERVED THERAPY; ECUADOR; HEALTH PROGRAM; HUMAN; INFECTION PREVENTION; INFECTION RISK; LONG TERM CARE; LOWEST INCOME GROUP; MEDICAL SOCIETY; MORBIDITY; MORTALITY; OUTCOMES RESEARCH; PREDICTION; PREVALENCE; PROBABILITY; PUBLIC HEALTH; SENSITIVITY ANALYSIS; SHORT COURSE THERAPY; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EID: 33244478500     PISSN: 00084263     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03405205     Document Type: Article

References (30)

1. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, et al. The growing burden of tuberculosis: Global trends and interactions with the HIV epidemic. Arch Intern Med 2003;163(9):1009-1021.
2. World Health Organization. Treatment of Tuberculosis: Guidelines for National Programmes, Second Edition. Geneva, Switzerland, 1997.
3. Suarez PG, Watt CJ, Alarcon E, Portocarrero J, Zavala D, Canales R, et al. The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru. J lnfect Dis 2001;184:473-478.
4. The effect of tuberculosis control in China. Lancet 2004;364(9432):417-422.
5. Vaca J, Peralta H, Gresely L, Cordova R, Kuffo D, Romero E, et al. DOTS implementation in a middle income country - Development and evaluation of a novel approach. Int J Tuberc Lung Dis 2005;9(5):521-527.
6. World Bank Website. http://www.worldbank.org/data/countrydata/countrydata.html. 2004 (Accessed on April 15, 2004).
7. Organizacion Panamericana de la Salud. Perfil de Salud del Pais - Ecuador. Pan-American Health Organization, editor. Washington, DC, 2001.
8. Lopez AD, Salomon J, Ahmad O, Murray CJL, Mafat D. Life Tables for 191 Countries: Data, Methods and Results. Geneva: World Health Organization, 2000. (GPE Discussion Paper Series: No.9).
9. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996;276(15):1253-1258.
10. Sutherland I. Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli. Adv Tuberc Res 1976;19:1-63.
11. Drummond MF, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press, 1987.
12. World Health Organization. Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2003. Geneva, Switzerland, 2003.
13. UNAIDS. Joint United Nations Programme on HIV/ AIDS. 2002. http://www.unaids.org/EN/default.asp (Accessed on April 15, 2004).
14. Insituto Nacional de Estadisticas y Census. Censo de poblacion y V de vivienda en 2001. Government of Ecuador, editor. http://www.inec.gov.ec. Quito, Ecuador, 2003 (Accessed on April 15, 2004).
15. Anuario de estatisticas vitales NACIMIENTOS Y DEFUNCIONES-INEC-2001. Programa Ampliado de Inmunizaciones MdSPdE, editor. Quito, Ecuador, 2001.
16. Global Drug Facility. First-line tuberculosis drugs & formulations currently supplied/to be supplied by the global TB drug facility. World Health Organization, editor. 2003. http://stoptb.org/GDF/drugsupply/drugs.available.html (Accessed on November 15, 2003).
17. Floyd K, Skeva J, Nyirenda T, Gausi F, Salaniponi F. Cost and cost-effectiveness of increased community and primary care facility involvement in tuberculosis care in Lilongwe District, Malawi. Int J Tuberc Lung Dis 2003;7(9 Suppl 1):S29-S37.
18. Floyd K, Wilkinson D, Gilks C. Comparison of cost effectiveness of directly observed treatment (DOT) and conventionally delivered treatment for tuberculosis: Experience from rural South Africa. BMJ 1997;315 (7120):1407-1411.
19. Schwartzman K, Oxlade O, Barr G, Grimard F, Acosta I, Baez J, et al. Domestic returns from investment in the control of tuberculosis in other countries. N Engl J Med 2005;353(10):1008-1020.
20. Elzinga G, Raviglione MC, Maher D. Scale up: Meeting targets in global tuberculosis control. Lancet 2004;363(9411):814-819.
21. DeRiemer K, Garcia-Garcia L, Bobadilla-del-Valle M, Palacios-Martinez M, Martinez-Gamboa A, Small PM, et al. Does DOTS work in populations with drug-resistant tuberculosis? Lancet 2005;365(9466):1239-1245.
22. Styblo K. The relationship between the risk of tuberculosis infection and the risk of developing infectious tuberculosis. Bull Int Union Tuberc 1985;60(3-4):117-119.
23. World Health Organization. Global Drug Resistance Surveillance - Country Data for Ecuador (2002). World Health Organization, Washington, DC 2004.
24. Sherman LF, Fujiwara PI, Cook SV, Bazerman LB, Frieden TR. Patient and health care system delays in the diagnosis and treatment of tuberculosis. Int J Tuberc Lung Dis 1999;3(12):1088-1095.
25. Yamasaki-Nakagawa M, Ozasa K, Yamada N, Osuga K, Shimouchi A, Ishikawa N, et al. Gender difference in delays to diagnosis and health care seeking behaviour in a rural area of Nepal. Int J Tuberc Lung Dis 2001;5(1):24-31.
26. Wandwalo ER, Mørkve O. Delay in tuberculosis case-finding and treatment in Mwanza, Tanzania. Int J Tuberc Lung Dis 2000;4(2):133-138.
27. Caminero Luna JA. Guia de la Tuberculosis Para Medicos Especialistas. Union Internacional contra la Tuberculosis y Enfermedades Respiratorias (UICTER), editor. 2003. Imprimé en France, Imprimerie Chirat. Dépot Légal 2003 No. 6432.
28. Floyd K, Blanc L, Raviglione M, Lee JW. Resources required for glotal tuberculosis control. Science 2002;295(5562):2040-2041.
29. Gupta R, Cegielski JP, Espinal MA, Henkens M, Kim JY, Lambregts-van Weezenbeek CSB, et al. Increasing transparency in partnerships for health - introducing the Green Light Committee. Tropical Medicine and International Health 2002;7(2):970-976.
30. Suarez PG, Floyd K, Portocarrero J, Alarcon E, Rapiti E, Ramos G, et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: A national cohort study in Peru. Lancet 2002;359(9322):1980-1989.